US 12122846
Chimeric antigen receptor for tumor targeting
granted A61KA61K2039/5156A61K2239/10
Quick answer
US patent 12122846 (Chimeric antigen receptor for tumor targeting) held by Fate Therapeutics, Inc. expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fate Therapeutics, Inc.
- Grant date
- Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/5156, A61K2239/10, A61K2239/13, A61K2239/21